One dose of 60 mg burosumab, an anti-FGF23 antibody, led to hyperphosphatemia requiring dose titration and 3 doses of burosumab normalized renal tubular maximum reabsorption rate of phosphate relative to glomerular filtration rate. This evidence concerns the gene FGF23 and hyperphosphatemia.